Impact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta-Analysis
Table 2
Pairwise comparisons of efficacy or safety in stem cells-treated patients compared with patients receiving standard therapy.
Groups versus control#
LVEF
MACE
Number of studies
Number of patients
MD (95% CI)
Number of studies
Number of patients
OR (95% CI)
6 months
1~7 days
23
862/673
71.8
2.57 (1.21~3.94)
16
768/571
0.0
0.51 (0.31~0.82)
1~3 days
6
142/127
36.2
1.26 (−0.66~3.18)
4
143/104
0.0
1.03 (0.30~3.47)
4~7 days
18
881/674
72.3
2.85 (1.61~4.09)
12
625/467
0.0
0.44 (0.26~0.76)
8~14 days
3
34/30
0.0
−0.84 (−4.31~2.64)
0
0
—
—
15~30 days
5
187/169
87.1
3.27 (−1.94~8.48)
4
167/140
0.0
1.79 (0.66~4.82)
Total
30
1083/872
73.6
2.53 (1.25~3.82)
19
935/711
0.0
0.66 (0.43~1.01)
12 months
1~7 days
10
311/240
50.0
4.34 (2.98~5.69)
9
342/296
12.7
0.31 (0.18~0.55)
1~3 days
—
—
—
—
—
—
—
—
4~7 days
10
311/240
50.0
4.34 (2.98~5.69)
9
342/296
12.7
0.31 (0.18~0.55)
8~14 days
2
10/10
0.0
2.33 (−3.95~8.62)
4
42/35
0.0
0.65 (0.15~2.84)
15~30 days
1
19/20
—
1.30 (−3.09~5.69)
1
21/21
—
2.11 (0.18~25.17)
Total
13
340/270
42.6
4.09 (2.83~5.34)
14
405/352
0.0
0.45 (0.27~0.76)
One study had arms belonging to 1~3 days’ group and another one belonging to 8~14 days’ group; one study had arms belonging to 8~14 days’ group and another one belonging to 15~30 days’ group. #Multiarm studies were divided into independent studies.
